Financial Data and Key Metrics Changes - ODDITY reported a 24% year-over-year revenue growth in Q3, reaching $148 million, exceeding guidance of 21% to 23% growth [16][19] - Adjusted diluted earnings per share increased to $0.40, surpassing guidance of $0.33 to $0.36 [18] - Gross margins expanded to 71.6%, up 170 basis points from the previous year, exceeding guidance of 68% [17] Business Line Data and Key Metrics Changes - Il Makiage experienced double-digit online revenue growth, with a target of $1 billion revenue by 2028 [11] - SpoiledChild is expected to generate $225 million in revenue for 2025, showing strong performance [12] - METHODIQ, the new brand, aims to launch 28 products addressing various skin conditions, with a focus on dermatology [8][9] Market Data and Key Metrics Changes - International revenue increased approximately 40% year-over-year in the first nine months of 2025, with significant growth in existing markets like the U.K. and Australia [11][24] - The U.S. still accounts for 83% of total revenue, indicating room for international expansion [23] Company Strategy and Development Direction - ODDITY is focused on expanding its international presence while responsibly managing growth across brands and geographies [23] - The company aims to leverage technology and innovation, particularly through ODDITY Labs, to enhance product offerings and consumer experience [14][52] - METHODIQ is positioned to transform the medical care system by providing high-efficacy treatments without traditional barriers [6][7] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in the industry but emphasized strong financial performance and growth potential [5][16] - The company raised its full-year guidance, expecting net revenue between $806 million and $809 million for 2025, representing 24% to 25% growth [19] - Management remains optimistic about the consumer environment, citing strong repeat purchase rates as a buffer against acquisition cost increases [40] Other Important Information - ODDITY plans to launch a major media campaign for METHODIQ, including a significant TikTok activation [10][89] - The company has a strong cash position with $793 million in cash and equivalents, plus $200 million available on undrawn credit facilities [19][60] Q&A Session Summary Question: Can you unpack the 40% year-to-date growth in international markets? - Management noted that 83% of revenue still comes from the U.S., with international growth primarily from existing markets like Canada and the U.K. [23][24] Question: How does METHODIQ plan to attract new customers? - METHODIQ is expected to draw customers from existing brands while also focusing on user acquisition [27] Question: What is the growth outlook for Il Makiage and SpoiledChild? - Management aims for sustained 20% growth across brands, with Il Makiage targeting $1 billion by 2028 [75] Question: How is the company addressing higher acquisition costs? - Management highlighted strong repeat purchase rates as a key factor in offsetting higher acquisition costs [40] Question: What is the financial profile of METHODIQ? - METHODIQ is expected to have a similar long-term growth framework as Il Makiage and SpoiledChild, with a focus on repeat business [50] Question: How will the company leverage its physician network for METHODIQ? - The company is currently using third-party networks for physicians and plans to integrate technology to enhance treatment outcomes [67]

Financial Data and Key Metrics Changes - The company reported a GAAP net loss of $13.7 million for Q3 2025, compared to a net loss of $13.6 million in Q3 2024 [31] - Revenue for Q3 2025 was $3.4 million, an increase from $3.0 million in the comparable period [31] - Non-GAAP gross loss for the reported period was $0.3 million, compared to a gross loss of $0.2 million in the comparable period, representing a gross loss margin of approximately 8% [32] Business Line Data and Key Metrics Changes - Revenue from teleradiology services for Q3 2025 was $3.1 million, with a gross profit of $0.1 million, compared to revenue of $2.6 million and a gross profit of $0.3 million in the comparable period [32] - Revenue from the sale and deployment of imaging systems and OEM services amounted to $175,000 for the reported period, with a gross loss of $1.7 million [35] - Revenue from AI solutions for the reported period was $0.1 million, with a gross loss of $1.9 million [35] Market Data and Key Metrics Changes - The company is expanding its presence in Europe with new agreements in the Czech Republic and France, indicating rising demand for its imaging ecosystem [7][15] - The company aims to deploy 100 systems worldwide by the end of 2025, with several systems pending regulatory approval [7] Company Strategy and Development Direction - The company is focused on building a comprehensive medical imaging portfolio, reinforcing its position in the medical AI sector, and deepening its foothold in the U.S. healthcare system [4][5] - The acquisition of VasoHealthcare IT is intended to enhance customer service and expand the company's operational capabilities [10][22] - The company is preparing to launch the next-generation Nanox.ARC X system, which is designed to meet diverse clinical needs and expand the addressable market [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving over $35 million in revenues for 2026, driven by strategic partnerships and the acquisition of VasoHealthcare IT [5][39] - The company anticipates that the AI business segment will achieve EBITDA break-even on a quarterly basis in 2026, while the overall company aims for break-even in 2027 [30][62] Other Important Information - The company has a strong presence planned at the RSNA annual meeting, where it will provide insights into its commercial progress and future strategy [13][21] - The company is actively engaged in clinical trials to support the use of its solutions in lung cancer detection and management [18][20] Q&A Session Summary Question: How many systems were in the field and performing scans that resulted in your revenue of $175,000? - The CEO mentioned that a few dozen systems were deployed, with some pending installation and regulatory approvals [44] Question: What types of agreements should we be thinking about in terms of those being lease versus capital sales? - The CFO indicated that the majority of agreements are expected to be MSES, with some CapEx sales anticipated [48] Question: Could you talk about how OpEx could look over the next four to six quarters? - Management indicated that sales and marketing expenses will increase due to deployment efforts, while R&D expenses will be more controlled [56] Question: Could you talk about Vaso and the types of customers they currently have? - The CEO stated that Vaso's customers are primarily medical-related, serving hospitals and imaging centers, presenting cross-selling opportunities [58] Question: Could you reiterate the break-even expectations for the AI business and ARC division? - Management reiterated that the AI business is expected to reach quarterly break-even in 2026, while the ARC division aims for break-even in 2027 [60][62]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $5.4 million, a 23% increase year-over-year from $4.4 million in Q3 2024, primarily driven by higher development services revenue [11] - Gross profit for the quarter was $0.9 million, or 16.5% of revenue, compared to $0.7 million, or 15.5% in the prior year [11] - Net loss was $2.7 million, or $0.24 per share, an improvement from a net loss of $10.3 million, or $0.98 per share in the prior year [13] - Cash position as of September 30, 2025, was $60 million, up from $44 million at year-end 2024 [15] Business Line Data and Key Metrics Changes - EscharEx's VALUE phase III trial for venous leg ulcers is progressing with a target enrollment of 216 patients across approximately 40 sites [4] - NexoBrid's manufacturing facility expansion has increased production capacity sixfold, with expectations to reach full operational capacity by year-end 2025 [8] - NexoBrid reported record quarterly revenue growth of 38% year-over-year and 26% sequentially in the U.S. [8] Market Data and Key Metrics Changes - Medicare's recent reduction in reimbursement rates for skin substitute products is expected to pressure that category, making EscharEx more attractive as it is regulated under the BLA pathway [7] - An updated market assessment estimates annual peak sales for EscharEx at about $831 million, reflecting robust clinical data and health economic benefits [7] Company Strategy and Development Direction - The company is focused on three strategic priorities: advancing the EscharEx trial, expanding NexoBrid manufacturing, and securing funding for its strategy [4] - The company aims to leverage market changes to position EscharEx as a leading product in the enzymatic debridement segment [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategic progress and operational readiness, positioning MediWound for growth in 2026 [16] - The company is actively monitoring enrollment trends in clinical trials and will update guidance as visibility improves [5] Other Important Information - The company completed a $30 million equity financing, enhancing its financial flexibility to execute long-term growth strategies [10] - The collaboration with BARDA on stockpiling and development activities is expected to resume following the end of a government shutdown [9] Q&A Session Summary Question: Changes in peak sales assumptions for SCAR-EX - Management clarified that the increase in peak sales estimate to $831 million is primarily due to updated pricing assumptions based on market access analysis, with no changes in patient volume or adoption rates [23][25] Question: Breakdown of revenue sources - Management indicated that detailed revenue breakdowns are not provided in quarterly calls, but gross margin improvements reflect a favorable revenue mix [44] Question: Update on BARDA contract status - The BARDA contract has not yet been awarded, but a proposal has been submitted, and the company is awaiting contract signing [46] Question: Impact of CPT code on adoption - Management noted that while a temporary CPT code is in place, a permanent code would enhance legitimacy and drive physician adoption and institutional acceptance [39]

Financial Data and Key Metrics Changes - Total revenue grew by 13% in Q4 2025, marking the highest year-over-year growth in nearly two years [16] - Adjusted OIBDA rose by 12%, with a slight decline in margins due to a revenue mix shift towards lower-margin artist services [17] - For the full year 2025, total revenue and adjusted OIBDA growth were both 8% on an adjusted basis [17] Business Line Data and Key Metrics Changes - Recorded music subscription streaming increased by 8.4%, driven by global subscriber growth and strong market performance [17] - Artist services revenue grew by 64%, showcasing the company's ability to support artists and expand revenue streams beyond core music [16] - Music publishing revenue grew by 13%, supported by double-digit growth across performance, mechanical, and sync [17] Market Data and Key Metrics Changes - In the U.S., market share increased by 0.6 percentage points year-over-year in Q4 2025 [5] - Globally, the company's share of the Spotify top 200 jumped by around 6 percentage points compared to fiscal 2024 [5] - The company achieved a 42% share of the Billboard Global 200 for 22 weeks during fiscal 2025 [9] Company Strategy and Development Direction - The company is focused on optimizing its operational structure to navigate a more globalized and digital environment, leading to market share gains and improved financial performance [6] - Investments are being prioritized in high-return areas of the core music business, with a balanced approach to driving performance across different markets and genres [19] - The company is committed to driving efficiency and enhancing margins through a reorganization and related cost savings program, targeting $200 million in annualized savings by 2026 [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to capitalize on the growing value of music, driven by healthy subscriber growth and improved wholesale pricing [21] - The introduction of generative AI is seen as both a challenge and an opportunity, with the company focusing on protecting artists' rights while exploring new revenue streams [10] - The outlook for 2026 includes expectations for strong top-line growth, driven by organic investments and M&A, alongside margin improvements from cost savings [22] Other Important Information - The company has signed agreements with four of the largest DSPs, which include wholesale price increases that will positively impact future revenues [17] - A significant focus is placed on enhancing the digital supply chain and modernizing infrastructure to support growth and operational efficiency [14] Q&A Session Summary Question: Update on rights monetization and WMG's role in capturing incremental value - Management sees this as an incremental opportunity for the music industry and emphasizes that WMG will be a driver of this change, focusing on licensed models and fair economic terms [27][28] Question: Building blocks behind top-line growth expectations for 2026 - Key growth drivers include wholesale price increases, robust M&A pipeline, and expansion in distribution, with confidence in leadership to accelerate growth [35][36] Question: Market share gains and performance of flagship labels - The company has seen broad-based market share growth across flagship labels and regions, driven by artist development and revitalization of catalogs [42][44] Question: Contribution of technology investments to growth outlook - Investments in technology are aimed at strengthening infrastructure to support high-volume business and enhance operational efficiency [56][57] Question: Balancing savings initiatives with market share gains - The company is increasing investments in core markets while achieving savings through operational efficiencies, ensuring a balance between cost management and growth [66][67] Question: AI as a potential threat and margin expansion guidance - Management acknowledges AI as both a threat and an opportunity, emphasizing the importance of large music companies in navigating this landscape [79] - The margin guidance reflects a net margin approach, focusing on organic growth drivers and cost savings [81]

Financial Data and Key Metrics Changes - In Q3, the company reported net sales of $1.6 billion, a decrease of 1% compared to the prior year, and adjusted earnings per diluted share of 35 cents, both below expectations [21][22] - The gross profit rate was 41.3%, down 220 basis points year-over-year, primarily due to a 260 basis point decrease in merchandise margin impacted by tariffs [23] - Operating income for Q3 was $161 million, down 26% from the previous year [24] - For Q4, the company expects sales to decline by high single digits and a gross profit rate of approximately 44.5% [25][26] - Full-year net sales guidance has been lowered from a growth of 1.5%-2.7% to a decline of low single digits, with adjusted earnings per diluted share guidance reduced from $3.35-$3.60 to at least $2.87 [27] Business Line Data and Key Metrics Changes - All core categories experienced low single-digit declines in Q3, indicating a need for focused investment in these areas [22] - U.S. and Canadian store net sales were flat at $1.2 billion, while direct net sales decreased by 7% to $299 million [22] - International net sales increased by 6% to $73 million, with system-wide retail sales growing by 16% [23] Market Data and Key Metrics Changes - Consumer sentiment is negatively impacting purchase intent, with recent data showing a decline in consumer confidence due to job loss concerns and affordability issues [25] - The competitive retail marketplace is highly challenging, with customers waiting for deeper discounts before making purchases [25] Company Strategy and Development Direction - The company is focusing on a consumer-first strategy with four pillars: creating innovative products, reigniting the brand, winning in the marketplace, and operating with speed and efficiency [20][10] - Plans include reducing SKU complexity, exiting non-core categories, and investing in core product categories to attract new consumers [12][68] - The company aims to launch on Amazon in early 2026 to reach new consumers and enhance brand visibility [15][16] Management's Comments on Operating Environment and Future Outlook - Management acknowledges that the current consumer environment is challenging and that the brand is not fulfilling its potential [5][34] - The company is committed to making necessary changes to return to growth, with a focus on long-term sustainable growth [18][51] - Management expects that the initiatives will take time to impact financial performance, with more visible results anticipated in the second half of 2026 [38][47] Other Important Information - The company plans to deliver $250 million in cost savings over the next two years, with over half identified for 2026 [17] - Capital expenditures for the year are projected at approximately $240 million, down from previous guidance [27] - Free cash flow expectation for the full year is approximately $650 million, reflecting current performance trends [28] Q&A Session Summary Question: What changed between when the CEO first joined and current expectations? - The CEO noted that the brand is not fulfilling its potential and that the focus on adjacencies has resulted in underinvestment in core categories [34][35] Question: What are the key KPIs for the new strategy? - The CEO highlighted total active consumers and growth in core categories as key metrics, along with improvements in digital traffic and dwell time [45][46] Question: How will the company balance investments and margins in 2026? - The CEO indicated that 2026 will focus on investing behind the brand while also unlocking $250 million in savings to fund these investments [51] Question: What is the plan for the Amazon partnership? - The CEO explained that the initial product assortment will include evergreen products, with plans to expand thoughtfully over time [62] Question: How will the company exit non-go-forward categories? - The CEO stated that SKU rationalization will begin in Q1 2026, focusing on consumer feedback to simplify the product offering [80][81]

Financial Data and Key Metrics Changes - The company reported a GAAP net loss of $13.7 million for Q3 2025, compared to a net loss of $13.6 million in Q3 2024 [32] - Revenue for Q3 2025 was $3.4 million, an increase from $3.0 million in the comparable period [32] - Non-GAAP gross loss for the reported period was $0.3 million, compared to a gross loss of $0.2 million in the comparable period, representing a gross loss margin of approximately 8% [33] Business Line Data and Key Metrics Changes - Revenue from teleradiology services for Q3 2025 was $3.1 million, with a gross profit of $0.1 million, compared to revenue of $2.6 million and a gross profit of $0.3 million in the comparable period [34] - Revenue from the sale and deployment of imaging systems and OEM services amounted to $175,000 for Q3 2025, with a gross loss of $1.7 million [35] - Revenue from AI solutions for Q3 2025 was $0.1 million, with a gross loss of $1.9 million, compared to revenue of $0.4 million and a gross loss of $1.6 million in the comparable period [35] Market Data and Key Metrics Changes - The company is expanding its presence in Europe with new agreements in the Czech Republic and France, indicating rising demand for its imaging ecosystem [7][14] - The company aims to deploy 100 systems worldwide by the end of 2025, with several systems pending regulatory approval [7] Company Strategy and Development Direction - The company is focused on building a comprehensive medical imaging portfolio, increasing revenues, and accelerating its path to profitability [4] - The strategy includes reinforcing its position in the medical AI sector and deepening its foothold in the U.S. healthcare system [4] - The acquisition of VasoHealthcare IT is intended to enhance the company's AI capabilities and customer service [10][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving over $35 million in revenues for 2026, driven by current business trajectory and new partnerships [5][30] - The company anticipates that the AI business segment will achieve EBITDA break-even on a quarterly basis in 2026, while the overall company expects to reach EBITDA break-even in 2027 [31] Other Important Information - The company is preparing to launch its next-generation platform, the Nano-X ARC X system, which is designed to meet diverse customer needs and expand the addressable market [8] - The company has entered into a multi-year volume supply agreement with Fabrinet to support scalable manufacturing of Nano-X ARC systems [30] Q&A Session Summary Question: How many systems were in the field and performing scans that resulted in your revenue of $175,000? - The revenue was generated from a combination of scans and OEM services, with a few dozen systems actively scanning [43][45] Question: What types of agreements should we be thinking about in terms of those being lease versus capital sales? - The majority of agreements are expected to be MSES, with some CapEx sales anticipated [47][48] Question: Could you talk about how OpEx could look over the next four to six quarters? - Investment in deployment efforts will increase, while R&D expenses are expected to be more controlled as focus shifts to commercialization [56] Question: Could you talk about Vaso and the types of customers they currently have? - Vaso's customers are primarily medical-related, serving hospitals and imaging centers, presenting cross-selling opportunities for Nano-X [58] Question: Could you reiterate the break-even targets for the AI business and ARC division? - The AI business is expected to reach quarterly break-even in 2026, while the ARC division aims for break-even in 2027 [61][63] Question: How should we think about the cadence of the $35 million revenue target for 2026? - Revenue is expected to start slowly in Q1 and ramp up over the quarters, achieving the target by Q4 [70]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $5.4 million, a 23% increase year-over-year from $4.4 million in Q3 2024 [11] - Gross profit for the quarter was $0.9 million, or 16.5% of revenue, compared to $0.7 million, or 15.5% in the prior year [11] - Net loss was $2.7 million, or $0.24 per share, compared to a net loss of $10.3 million, or $0.98 per share in the prior year [13] - Cash position as of September 30, 2025, was $60 million, up from $44 million at year-end 2024 [15] Business Line Data and Key Metrics Changes - EscharEx's VALUE Phase III trial for venous leg ulcers is progressing with a target of 216 patients across approximately 40 sites [4] - NexoBrid's manufacturing facility expansion has increased production capacity sixfold, with full operational capacity expected by year-end 2025 [8] - NexoBrid reported record quarterly revenue growth of 38% year-over-year and 26% sequentially [8] Market Data and Key Metrics Changes - Medicare's recent reduction in reimbursement rates for skin substitute products is expected to pressure that category, making EscharEx more attractive as it is regulated under the BLA pathway [7] - The updated U.S. market access assessment estimates annual peak sales for EscharEx at about $831 million, reflecting robust clinical data and health economic benefits [7] Company Strategy and Development Direction - The company is focused on three strategic priorities: advancing the EscharEx trial, expanding NexoBrid manufacturing, and securing funding for its strategy [4] - The company aims to leverage market changes to position EscharEx as a leading product in the enzymatic debridement segment [7] - The collaboration with BARDA is expected to resume following the government shutdown, which will support the development of NexoBrid [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning for growth in 2026, citing consistent execution and strategic progress [16] - The company is actively monitoring enrollment trends in clinical trials and will update guidance as visibility improves [5] Other Important Information - The company completed a $30 million equity financing, enhancing its financial flexibility to execute long-term growth strategies [10] - The TGA in Australia approved NexoBrid for use in both adult and pediatric patients, expanding its global presence [9] Q&A Session Summary Question: Changes in peak sales assumptions for EscharEx - Management clarified that the increase in peak sales estimate to $831 million is primarily due to updated pricing assumptions based on market access analysis, with no changes in patient volume or adoption rates [25] Question: Breakdown of revenue sources - Management indicated that detailed revenue breakdowns are not provided in quarterly reports, but gross margin improvements reflect a favorable revenue mix [44] Question: Status of BARDA contract - The BARDA contract has not yet been awarded, but the company is awaiting the signing of the proposal submitted for a 10-year contract [46] Question: Impact of CPT code on adoption - Management noted that while a temporary CPT code is in place, a permanent code would enhance legitimacy and drive physician and institutional adoption of NexoBrid [39]

Financial Data and Key Metrics Changes - Fiscal 2025 Adjusted EBITDA reached $352 million, an increase of $28 million or 8% compared to fiscal 2024, with a margin of 13.2%, representing a 260 basis point improvement from fiscal 2023 [14][15] - Adjusted EBITDA margin expanded by 150 basis points year-over-year, marking consecutive years of margin expansion [15][20] - SG&A expense as a percentage of revenue improved by 180 basis points since 2023, reflecting operational efficiencies [12][16] Business Line Data and Key Metrics Changes - Customer retention improved to approximately 83%, a 400 basis point increase since the start of the transformation two years ago [8][4] - The company added about 100 new sellers in fiscal 2025, with plans to continue expanding the sales force by approximately 500 net new hires through 2030 [9][10] - The land maintenance revenue is expected to grow by 1%-2% in fiscal 2026, driven by the growing sales force and improved customer retention [21] Market Data and Key Metrics Changes - The development segment is expected to see revenue growth in the range of flat to +2%, supported by a healthy backlog and benefits from cold starts [22] - Snow revenue is anticipated to be between $190 million and $220 million, reflecting a shift to more fixed fee contracts [22] Company Strategy and Development Direction - The company is focused on delivering sustainable and profitable top-line growth by investing in frontline employees and expanding the sales force [6][11] - A disciplined approach to capital allocation is emphasized, with an increased share repurchase authorization from $100 million to $150 million [4][19] - The fleet management strategy has been a key focus, with over $300 million invested to refresh aging equipment, leading to improved operational efficiency and employee morale [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the return of discretionary spending in ancillary services and the overall growth potential for the business in 2026 [28][29] - The company is confident in its ability to grow, citing improvements in employee and customer retention as critical factors [84][85] - Management acknowledged potential challenges from seasonal fluctuations but remains focused on leveraging improvements in service delivery and operational efficiencies [28][29] Other Important Information - The company has a strong balance sheet with net leverage remaining at 2.3x and no long-term maturities until 2029, providing ample liquidity for investments [19][20] - The midpoint of the margin guidance implies a 310 basis point improvement over the last three years, reinforcing the commitment to expanding margins [23] Q&A Session Summary Question: How did performance in discretionary areas of land maintenance trend in Q4? - Management noted optimism in discretionary spending returning, with positive feedback from frontline workers and customers regarding new fleet investments [27][28] Question: What is the expected productivity ramp for new sales hires? - New sellers typically see limited productivity in the first six months, with improved performance expected after a year, targeting $1.5 million in annual sales for seasoned sellers [30][31] Question: How far along is the company in improving employee retention? - Employee retention has improved significantly, with further potential for enhancement, aiming for a more normalized level for the high-turn workforce [41][43] Question: What impact has the new tax bill had on capital investment? - The company benefited from tax savings to accelerate fleet refresh investments, with expectations to normalize capital expenditures in the coming years [45][46] Question: What is the timeline for the rollout of the field service management system? - The rollout is expected to be completed in the first quarter of the new year, aimed at increasing efficiency and capacity rather than cost savings [68][69] Question: How are project delays in the development business being managed? - Management indicated that while there have been delays, they expect to see growth in the development business as new branches open and backlogs are addressed [71][72]

Financial Data and Key Metrics Changes - Net revenue for the first half of fiscal year 2025 reached $38 million, reflecting a 15% year-on-year growth [18] - Income from operations was $471,000, marking a 108.1% increase compared to the same period last year [18][20] - Operating cash flow turned positive at $2.60 million, a significant improvement from a negative figure in the same period last year [22] Business Line Data and Key Metrics Changes - The sports school business generated revenue of $27 million, an 8.5% year-on-year increase, driven by a rise in membership and event participation [20] - The social business achieved sales revenue of $11 million, a 35.4% year-on-year increase, primarily due to an increase of 114 schools contracting for school club support [20] Market Data and Key Metrics Changes - The proportion of social business revenue to total revenue increased from 24% in fiscal year 2023 to 28% in the first half of fiscal year 2025, indicating growth in this segment [18] - The company supported 349 schools nationwide as of the end of June 2025, a 48.5% year-on-year increase [12][19] Company Strategy and Development Direction - The company aims to expand its sports school business internationally, leveraging its recent IPO on NASDAQ to facilitate this growth [10][26] - The focus is on developing a sports and social business that addresses social issues through sports, with a strong emphasis on non-cognitive skill development for children [11][29] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in the school club support business, driven by national policy reforms aimed at transitioning club activities to private sector management [24][25] - The company anticipates net sales for the full year 2025 to be between $80.2 million and $82.6 million, representing a growth of 12%-15% compared to the full year of 2024 [21] Other Important Information - The company has been recognized as the number one provider in Japan for both the number of sports school members and the number of schools supported [10][12] - The company operates 18 facilities nationwide for after-school daycare services, focusing on children with developmental disabilities [13] Q&A Session Summary Question: What do you think about the future of social business, especially school club support business? - The company plans to continue growing the school club support business, targeting public junior high schools in designated cities and leveraging its market leader position [24] Question: Please tell us about your overseas business expansion in the U.S. and other countries. - The company intends to expand its sports schools overseas, considering various sports popular in each region, not limited to soccer [26] Question: Are you considering listing in Japan? - The company is not ruling out the possibility of a future listing in Japan but is currently focused on its recent NASDAQ listing [27] Question: Why is the operating profit margin low? - The company incurs costs related to solving social issues but plans to improve this margin through business expansion and operational efficiency [27]

Financial Data and Key Metrics Changes - Total revenue grew by 13% in Q4, marking the highest year-over-year growth in nearly two years [16] - Adjusted OIBDA rose by 12%, with a slight decline in margins due to a revenue mix shift towards lower-margin artist services [17] - For the full year 2025, total revenue and adjusted OIBDA growth were both 8% on an adjusted basis [17] Business Line Data and Key Metrics Changes - Recorded music subscription streaming increased by 8.4%, driven by global subscriber growth [17] - Artist services revenue grew by 64%, showcasing the company's ability to support artists and expand revenue streams beyond core music [16] - Music publishing revenue grew by 13%, supported by double-digit growth across performance, mechanical, and sync [17] Market Data and Key Metrics Changes - In the U.S., market share increased by 0.6 percentage points year-over-year in Q4 [5] - Globally, the company's share of the Spotify top 200 increased by approximately 6 percentage points compared to fiscal 2024 [5] - The company achieved a 42% share of the Billboard Global 200 for 22 weeks during fiscal 2025 [9] Company Strategy and Development Direction - The company is focused on optimizing its operational structure to navigate a more globalized and digital environment [6] - Investments are being prioritized in markets with the most attractive return profiles, leading to market share growth in every key region [19] - The company is committed to driving efficiency and has a cost savings program targeting $200 million in annualized savings by 2026 [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth strategy, highlighting the importance of adapting to the evolving landscape, including the impact of generative AI [10] - The outlook for 2026 includes expectations for strong top-line growth driven by organic investments and M&A opportunities [22] - Management emphasized the importance of protecting artists' rights while exploring new revenue streams through AI [11] Other Important Information - The company has signed agreements with four of the largest DSPs, which include wholesale price increases that will positively impact future revenues [17] - A significant focus is placed on enhancing the digital supply chain and modernizing infrastructure to support growth [14] - The company is actively pursuing M&A opportunities to accelerate growth and enhance margins [20] Q&A Session Summary Question: Update on rights monetization and WMG's role in capturing incremental value - Management sees this as an incremental opportunity for the music industry and is determined to be proactive in driving change [27] Question: Building blocks behind top-line growth expectations for 2026 - Key drivers include global subscriber growth, wholesale price increases, and a robust pipeline of accretive M&A [35] Question: Market share gains and performance of flagship labels - Market share growth has been broad-based across flagship labels and regions, with a focus on artist development and catalog revitalization [42] Question: M&A plans and distribution as a growth driver - The company has a strong pipeline for M&A and is confident in accelerating growth in distribution under new leadership [50] Question: Investments in technology and their contribution to growth - Investments in technology are focused on strengthening infrastructure to support high-volume business and enhance operational efficiency [56] Question: Variability in licensing terms across DSPs - There is more standardization in deal terms now, but the company strives for a fair marketplace where partners pay similar prices for content [64] Question: Balancing savings initiatives with market share gains - The company is increasing investments in core markets while achieving savings through operational efficiencies [66] Question: AI as a potential threat and opportunity - Management acknowledges the dual nature of AI as both a threat and an opportunity, emphasizing the importance of shaping the industry to benefit artists and songwriters [79]